Issue Cover

Sales & Marketing

The latest pharmaceutical sales and marketing news

Articles

AstraZeneca pays C4X an $11m milestone payment
AstraZeneca pays C4X an $11m milestone payment

C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca, which was triggered by the preclinical progress of C4XD’s NRF2 activator programme.

7 February 2024Sales & Marketing
Aiolos Bio to be acquired by GSK for $1bn
Aiolos Bio to be acquired by GSK for $1bn

GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an initial $1bn upfront payment along with up to $400m in success-based regulatory milestone payments.

7 February 2024Sales & Marketing
Inhibrx to be acquired by Sanofi for approximately $1.7bn
Inhibrx to be acquired by Sanofi for approximately $1.7bn

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for Sanofi to acquire Inhibrx following the spin-off of non-inbrx-101 assets into New Inhibrx.

7 February 2024Sales & Marketing
Harpoon Therapeutics set to be acquired by Merck for approximately $680m
Harpoon Therapeutics set to be acquired by Merck for approximately $680m

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a definitive agreement for Merck, through a subsidiary, to acquire Harpoon for an approximate total equity value of $680m or $23 per share.

7 February 2024Sales & Marketing
Autifony and Jazz Pharmaceuticals enter global licence and collaboration agreement
Autifony and Jazz Pharmaceuticals enter global licence and collaboration agreement

Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz Pharmaceuticals for up to $770.5m, with the intention of discovering and developing drug candidates to target two different ion channel targets associated with neurological disorders.

24 November 2023Sales & Marketing
Propella Therapeutics to be acquired by Astellas Pharma for $175m
Propella Therapeutics to be acquired by Astellas Pharma for $175m

Astellas Pharma and Propella Therapeutics have announced that they have entered a merger agreement in which Astellas will acquire Propella for approximately $175m.

24 November 2023Sales & Marketing
Roche to acquire Telavant for $7.1bn
Roche to acquire Telavant for $7.1bn

Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by Roivant sciences and Pfizer.

24 November 2023Sales & Marketing
$175m raised by Avalyn Pharma in Series C financing for inhalation therapies
$175m raised by Avalyn Pharma in Series C financing for inhalation therapies

US-based clinical stage biopharmaceutical company Avalyn Pharma has announced that it has raised $175m in series c financing to continue its portfolio of inhalation therapies.

1 November 2023Sales & Marketing
€45m series B funding raised by Acesion Pharma
€45m series B funding raised by Acesion Pharma

Acesion Pharma has announced that it has closed an oversubscribed €45m series b financing round.

1 November 2023Sales & Marketing
Mirati Therapeutics to be acquired by BMS for $4.8bn
Mirati Therapeutics to be acquired by BMS for $4.8bn

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS will acquire Mirati for $58 per share, or a total value of $4.8bn.

1 November 2023Sales & Marketing
POINT Biopharma to be acquired by Eli Lilly for $1.4bn
POINT Biopharma to be acquired by Eli Lilly for $1.4bn

Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT to expand its pipeline of clinical and preclinical-stage radioligand therapies for the treatment of cancer.

1 November 2023Sales & Marketing
Alfasigma acquires Intercept Pharmaceuticals for approximately $800m
Alfasigma acquires Intercept Pharmaceuticals for approximately $800m

Alfasigma and Intercept Pharmaceuticals have announced that they have entered into a definitive merger agreement, meaning Alfasigma will acquire Intercept for $19 per share.

1 November 2023Sales & Marketing